RxDoctor Payments Data

Gabriel Valle, MD

Nephrology · Fort Lauderdale, FLNPI 1578669925

Payments from drug & device makers

$1,390in general payments, 2019–2025

Across 40 payments — averaging $34.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$250
  • Travere Therapeutics, Inc.$179
  • Bard Peripheral Vascular, Inc.$139
  • Mallinckrodt Hospital Products Inc.$127
  • Boehringer Ingelheim$125
  • Novo Nordisk$125
  • plus $445 from 10 others

What the payments were for

  • Food & beverage$1,22588%
  • Education$16512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,390 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$262,915
Medicare patients
596
Services billed
2,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol33$38,301
VelphoroSucroferric Oxyhydroxide19$29,489
Tacrolimus30$8,943
LinzessLinaclotide16$8,449
LokelmaSodium Zirconium Cyclosilicate13$7,887
Sevelamer Carbonate25$7,114
Clonidine36$5,184
Megestrol Acetate12$3,075
Nifedipine ErNifedipine97$2,826
Labetalol Hcl41$1,830
Febuxostat13$1,759
Spironolactone-HctzSpironolact/Hydrochlorothiazid39$1,740
Torsemide106$1,274
Losartan Potassium132$1,222
Metoprolol Succinate39$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$61$46,18846 claims
Fresenius USA Marketing, Inc.Velphoro$58$29,48919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 756 nephrology providers in Florida.

Other nephrology in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →